FK-866 - Order from Adipogen

JavaScript seem to be disabled in your browser.

You must have JavaScript enabled in your browser to utilize the functionality of this website.

Actions

Select size:

1 mg

5 mg

* Required Fields

Amount:

Call	+1 858 457-8383
Fax	+1 858 457-8484
Contact Us!

Product Datasheet

MSDS

Additional Information

Product Data
Synonyms	K 22.175; FK866; APO866; WK175; N-[4-(1-Benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2E-propenamide
Properties
Formula	C₂₄H₂₉N₃O₂
MW	391.5
CAS	658084-64-1
Purity	≥98% (NMR)
Appearance	White to yellow solid. (Tends to easily liquefy.)
Solubility	Soluble in 100% ethanol, dimethylformamide (40 mg/ml) or DMSO (25 mg/ml); sparingly soluble in aqueous buffers.
InChi Key	KPBNHDGDUADAGP-VAWYXSNFSA-N
Product Type	Chemical
Shipping and Handling
Shipping	BLUE ICE
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Hygroscopic. Keep under inert gas.
Use/Stability	Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS	Download

Product Description

Nampt/visfatin inhibitor [1].
Inhibitor of NAD⁺ biosynthesis [1].
Inhibits the enzyme/substrate complex and the free enzyme (K_i = 0.4 nM and K_i = 0.3 nM, respectively) [1].
Apoptosis inducer [1].
Autophagy inducer [2].
Causes premature senescence [3].
Angiogenesis inhibitor [4].

Product References

FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis: M. Hasmann & I. Schemainda; Cancer Res. 63, 7436 (2003) NAD depletion by FK866 induces autophagy: R.A. Billington, et al.; Autophagy 4, 385 (2008) Extension of human cell lifespan by nicotinamide phosphoribosyltransferase: E. van der Veer, et al.; J. Biol. Chem. 282, 10841 (2007) Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma: J. Drevs, et al.; Anticancer Res. 23, 4853 (2003)

No reviews for this product yet.